Brief: Valbiotis FY Turnover Up At €785.000 Euros

Valbiotis SA

15/03/2023 17:34

March 15 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS PUBLISHES ITS 2022 ANNUAL RESULTS AND PROVIDES
AN
UPDATE ON ITS STRATEGIC ROADMAP
    * A CASH POSITION OF MORE THAN EUR 20 MILLION AT END OF
2022,
WHICH PROVIDES COMPANY FINANCIAL VISIBILITY UNTIL END OF FIRST
HALF OF 2024
    * CONTINUED STRUCTURING OF COMPANY TOWARDS FIRST COMMERCIAL
LAUNCHES IN EARLY 2024, BOTH IN FRANCE AND THROUGH INTERNATIONAL
PARTNERSHIPS
    * A DECISIVE YEAR ON THE CLINICAL FRONT WITH THE RESULTS OF
THE
PHASE II/III REVERSE-IT STUDY ON TOTUM•63, EXPECTED BEFORE THE
END OF THE FIRST HALF OF 2023
    * IN 2022, VALBIOTIS' TURNOVER MORE THAN DOUBLED TO EUR
785,000
    * OTHER OPERATING INCOME INCLUDES EUR 1,692,000 IN RESEARCH
TAX
CREDIT, VIRTUALLY UNCHANGED FROM PREVIOUS YEAR, AND EUR 137,000
IN GRANTS
    * CASH FLOW FROM OPERATING ACTIVITIES AMOUNTED TO €
-9,192,000 FOR
2022
    * AS OF DECEMBER 31, 2022, VALBIOTIS HAD A CASH POSITION OF
€20,828,000, CLOSE TO ITS LEVEL AT THE END OF 2021
    * EXPECTS TO MEET ITS FINANCIAL DEBT REPAYMENT SCHEDULE,
WITH AN
ESTIMATED END-OF-CASH HORIZON AT THE END OF THE FIRST HALF OF
2024
    * PARTNERSHIP FOR TOTUM•070 EXPECTED TO BE SIGNED IN THE
SECOND
HALF OF 2023

Source text for Eikon:  ID:nNDL37Z5sV 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))